ABSTRACT
OBJECTIVE: To investigate the inhibitory effects of recombinant human endostatin (rh-ES) on cell adhesion, metastatic potential and invasiveness of hepatocellular carcinoma HCCLM6 cells in vitro. METHODS: The changes in the cell proliferation status of HCCLM6 cells treated with different concentrations of rh-Endostatin in vitro was measured with MTT assay, and their invasiveness and migration were assayed using transwell cell culture chamber. The cell adhesion assay was carried out on 96-well plate precoated with matrigel. RESULTS: Rh-ES showed inhibitory effect against the proliferation of HCCLM6 cells after a 72-h treatment. The adhesion, metastatic potential and invasiveness of the cells were obviously inhibited by rh-Endostatin in a dose-dependent manner. CONCLUSION: Rh-ES inhibits the adhesion, invasiveness and migration of hepatocellular carcinoma cells in vitro, and the mechanism needs further investigation.
Subject(s)
Cell Movement/drug effects , Cell Proliferation/drug effects , Endostatins/pharmacology , Antineoplastic Agents/pharmacology , Carcinoma, Hepatocellular/pathology , Carcinoma, Hepatocellular/physiopathology , Cell Adhesion/drug effects , Cell Line, Tumor , Cell Survival/drug effects , Dose-Response Relationship, Drug , Endostatins/genetics , Humans , Liver Neoplasms/pathology , Liver Neoplasms/physiopathology , Neoplasm Invasiveness , Neoplasm Metastasis , Recombinant Proteins/pharmacologyABSTRACT
<p><b>OBJECTIVE</b>To evaluate the feasibility and efficacy of radioimmunotherapy with 131 I-labeled humanized anti-HBsAg Fab (131 I-anti-HBsAg Fab) combined with 131 I-labeled anti-nucleus antigen monoclonal antibody chTNT (131 I-chTNT) in nude mice bearing human hepatocellular carcinoma.</p><p><b>METHODS</b>Nude mice bearing subcutaneous human hepatocellular carcinoma xenografts were treated by intratumoral injection of 131 I-anti-HBsAg Fab and/or 131 I-chTNT, and the changes in the tumor size and alterations in the radioactivity concentration in the tumor and non-tumor tissues were observed.</p><p><b>RESULTS</b>The tumor inhibition rate in mice treated with 131 I-anti-HBsAg Fab combined with 131 I-chTNT (73.09%) was significantly higher than that in mice treated with 131 I-anti-HBsAg Fab (47.8%) or 131 I-chTNT (54.26%) alone. Combined treatment also resulted in significantly higher tumor-to-normal radioactivity concentration ratios than the treatment with the single agents.</p><p><b>CONCLUSION</b>Intratumoral injection with 131 I-labeled monoclonal antibodies can increase the radioactivity concentration in the tumor and enhance the efficacy of the radioimmunotherapy in nude mice bearing human hepatocellular carcinoma.</p>
